Related Experiment Video

Updated: May 8, 2026

Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
09:15

Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells

Published on: October 20, 2022

Inhibiting MDM2 enhances RIPK3-mediated necroptosis and synergizes with immune checkpoint blockade therapy

Yingxin Wu1,2, Hanyang Yu1, Zongxu Zhang3

  • 1School of Basic Medical Sciences, Tsinghua Medicine, Tsinghua University, Beijing, China.

Iscience
|May 7, 2026
PubMed

Insights

Mouse double minute 2 (MDM2) suppresses necroptosis, a programmed cell death pathway that boosts anti-tumor immunity. Inhibiting MDM2 enhances necroptosis, promoting T cell responses and improving cancer immunotherapy efficacy, even in p53-deficient tumors.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Necroptosis, a programmed cell death pathway, enhances tumor immunogenicity.
  • Identifying regulators of necroptosis is crucial for developing novel cancer immunotherapies.

Purpose of the Study:

  • To identify druggable regulators of tumor necrosis factor α (TNF-α)-induced necroptosis.
  • To investigate the role of mouse double minute 2 (MDM2) in regulating necroptosis and its therapeutic potential in cancer.

Main Methods:

  • Small-molecule inhibitor screen to identify necroptosis regulators.
  • Genetic deletion and pharmacologic inhibition of MDM2 in cancer models.
  • Assessment of necroptosis, T cell infiltration, and tumor microenvironment (TME) remodeling.
  • Combination therapy studies with anti-PD-1 blockade.

Main Results:

  • MDM2 was identified as a suppressor of TNF-α-induced necroptosis.
  • MDM2 inhibition enhanced necroptosis via RIPK1 and RIPK3 degradation, independent of p53.
  • MDM2 deficiency promoted tumor cell necroptosis, TME inflammation, and CD8+ T cell infiltration, improving tumor control.
  • Combination of MDM2 inhibition and anti-PD-1 blockade enhanced therapeutic efficacy in cold tumors.

Conclusions:

  • MDM2 is a key regulator of necroptosis and a potential therapeutic target for cancer immunotherapy.
  • Targeting MDM2 can enhance anti-tumor immunity and improve responses to immune checkpoint blockade, particularly in p53-deficient settings.
Keywords:
cancercell biologyimmune response

More Related Videos

Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis08:55

Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis

Published on: August 7, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...